Next Generation Bioluminescent Probes: Ultrasensitive Biomarker Detection In Vivo and In Vitro Assays-John Bashkin-03/27/2012 - 8:30am

Event Information
Event Topic: 
Next Generation Bioluminescent Probes: Ultrasensitive Biomarker Detection In Vivo and In Vitro Assays
Event Date: 
03/27/2012 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyale, CA
Speaker Information
Event Speaker: 
John Bashkin
Event Speaker Title: 
Vice President of Business Development
Event Speaker Company: 
Event Speaker Bio: 

John Bashkin, PhD

Dr. Bashkin has 18 years of experience in technology, product, and business development for life sciences and medical devices. He is currently VP of Business Development at Zymera, Inc. and is serving on the Life Sciences Committee for Astia. He has also held senior business development positions at SRI International, Artificial Muscle, Inc. and Triple Ring Technologies. While at SRI, Dr. Bashkin headed up business development efforts for life science and medical device technologies from across the institute as well as led his own NIH-funded research program and served on the IP Committee for the Institute. With Artificial Muscle, he was responsible for all corporate contract matters as well as business development for the medical industry. At Triple Ring Technologies, he served as VP Strategic Business Development, defining strategies for business growth and managing strategic relationships. Prior to joining SRI, Dr. Bashkin was a senior researcher at Molecular Dynamics and Amersham, where he led the development of the first high-throughput DNA sequencing system. He received his B.S. in Chemistry and Physics from the University of Arizona, his Ph.D. in Chemistry from Indiana University, and held post-doc positions at the University of Rochester and Johns Hopkins University. In 2000, he received his MBA from Santa Clara University. Dr. Bashkin is a co-inventor on six issued U.S. patents and co-author on more than 20 publications.

Event Details
Event Details: 

Bioluminescent Resonance Energy Transfer (BRET) probes combine a recombinant form of renilla luciferase (Luc8) with quantum dots. Luc8 is a form of luciferase that exhibits improved light output and serum stability over traditional versions of the enzyme. By tethering Luc8 to quantum dots, efficient energy transfer occurs from the Luc8 to the quantum dot, providing a means to multispectral imaging both in vitro and in vivo, in the near IR, without an external illumination source. This eliminates tissue autofluorescence and facilitates deep tissue imaging while probe stability enables multiple time-point measurements over several days. Probes can be targeted; conjugated with biomolecular recognition molecules (antibodies and peptides), or activity-based. The design and applications of these new reagents will be discussed.